Takeda Completes Ariad Buy

Feb 16, 2017

Japan's Takeda has announced the completed acquisition of Ariad Pharmaceuticals, for $5.2 billion -- $24 per share in cash.

After Takeda made several offers, the purchase was made at a 75 percent premium over Massachusetts-based Ariad's previous closing stock price.

The acquisition will add Ariad's innovative targeted therapies and R&D capabilities to Takeda's oncology business. Of particular interest to Takeda is the global potential of Ariad's brigatinib, an investigational drug product, which could become a best-in-class ALK inhibitor for non-small cell lung cancer with the potential to achieve peak annual sales of over $1 billion.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments